Ustekinumab's Benefits In Psoriatric Arthritis Last Through 1 Year

Ustekinumab's benefits in psoriatric arthritis last through 1 year

MDedge: news and insights for busy physicians

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab

Annals of the Rheumatic Diseases

Ustekinumab safe and effective for psoriatic arthritis.

Guselkemab vs. Ustekinumab in PsA: Dr. Richard Conway

Janssen Gets USFDA Nod For Psoriatic Arthritis Treatment STELARA For Pediatric Patients

Medical Dialogues

Ustekinumab less effective for psoriasis in lower extremities, according to study

Chronicle Companies

Jury Still Out on Cardiovascular Risk of Ustekinumab for Psoriasis

MDedge: news and insights for busy physicians

STELARA ® Approved by the FDA to Treat Pediatric Patients with Active Psoriatic Arthritis

HPR

Ustekinumab effective against moderate-to-severe plaque psoriasis in adolescent

infocusrx today

How do I prevent getting infections when taking Stelara?

Be Healthy! Be Happy! with Dr. Jim

#ustekinumab | Uses, Dosage, Side Effects & Mechanism | Stelara

Advances in Psoriatic Arthritis and Spondyloarthropathy

ClevelandClinicCME

PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biol... | RTCL.TV

Medicine RTCL TV

Overview - Stelara a Prescription Medication Used to Treat Adults with Psoriasis

Apremilast effects sustained at 1 year in psoriatic arthritis

MDedge: news and insights for busy physicians

Ustekinumab

Stelara (ustekinumab) Injection

STELARA® (ustekinumab) for Plaque Psoriasis Treatment

Centros de cirugía y medicina estética

Positioning anti-IL-12 and anti-IL-23 inhibitors

Clinical Assessment and Principles of Management of Psoriatic Arthritis

ClevelandClinicCME